Faruqi & Faruqi, LLP Announces Final Court Approval of Settlement in Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Co., et al. No. 12-3824 (E.D. Pa.)
Faruqi & Faruqi, LLP is pleased to announce the Court’s final approval of a settlement in Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Co., et al., Civ. No. 12-3824 (E.D. Pa.) (the “Settlement”). This case involves claims that Defendants violated the antitrust laws relating to the sale of prescription pharmaceutical Doryx® to direct purchasers such as wholesalers. The Settlement provides for $15,000,000 in cash to be paid to the direct purchaser class members, who are defined in the Settlement as entities that purchased Doryx® directly from any of the Defendants at any time between July 18, 2008 and December 31, 2013 (the “Class”). Notice was mailed to Class members on March 4, 2014 and Class members had until April 3, 2014 to object to or opt-out of the Settlement. The Court, in its September 16, 2014 Order, among other things, certified the Class under Federal Rule of Civil Procedure 23, awarded reimbursement of expenses and attorneys’ fees to Class Counsel in the amount of 33 1/3% of the Settlement amount plus accrued interest. Following entry of the final judgment, claim forms will be mailed to Class members. Below are the September 16, 2014 Order granting final approval to the Settlement, Class Notice, the Settlement Agreement, the Court’s February 18, 2014 Order preliminarily approving the Settlement, the Consolidated Amended Complaint filed on August 13, 2013, Plaintiffs’ motion for preliminary approval of the Settlement, Plaintiffs’ motion for final approval of the Settlement and Plaintiffs’ motion for attorneys’ fees, reimbursement of expenses and incentive awards to class representatives.